# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BD (Becton, Dickinson and Company) will acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash....
Critical Care has approximately 4,500 employees with most based in Irvine, California. In 2023, the business generated more tha...
With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care. Edwards will use the aft...
Goldman Sachs analyst David Roman initiates coverage on Edwards Lifesciences (NYSE:EW) with a Buy rating and announces Price...
Citigroup analyst Joanne Wuensch upgrades Edwards Lifesciences (NYSE:EW) from Neutral to Buy and raises the price target fro...